allogenic t cell-depleted hematopoietic stem cells
Cell therapyexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2012 (NCT01759732)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- LymphocytesTissue restoration
tissue restoration - lymphocytes
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- allogenic t cell-depleted hematopoietic stem cells
- cd3-depleted hematopoietic cell
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02600208 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2015 | Medical College of Wisconsin, Miltenyi Biotec, Inc. |
| NCT02158767 | N/A | Dec 1, 2013 | Case Western Reserve University, National Cancer Institute (NCI) |
| NCT01759732 | Phase 2 | Sep 1, 2012 | University of Ulsan |
| NCT01881334 | N/A | — | Duke University, Miltenyi Biotec, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Miltenyi Biotec, Inc. | For profit | 2 | 0 | 2 | 2015 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | — |
| Medical College of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 2015 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2013 |
| University of Ulsan | Academic/Hospital | 1 | 1 | 1 | 2012 |
6 organizations
Page 1 / 1